ArticleCurrent protocols2026
A Randomized Double-Blind Placebo-Controlled Multicentric Clinical Trial of an Ayurvedic Intervention, Varadi Kwatha Ghana Vati, as an Adjunct vs Treatment as Usual in the Management of Type-2 Diabetes Mellitus: A Study Protocol.
Article in Current protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDiabetes mellitus is a major and growing contributor to morbidity and mortality. Indian Council of Medical Research-India Diabetes study reports a prevalence of 11.4% for diabetes and 15.3% for prediabetes in India. Diabetes is described in depth in ancient Ayurveda texts, from aetiology to pre-clinical, clinical features, complications, and its stage-wise management. The current study has the potential to explore whether lowering glycemic control at the level of haemoglobin affects endogenous insulin production by examining C-peptide and insulin levels.
methodsThe current study is designed as a randomized, double-blind, placebo-controlled, multicenter, two-arm clinical trial enrolling 220 participants across two Indian sites. Adults with diagnosed Type-2 diabetes mellitus on oral hypoglycemic agents (OHAs) with glycated haemoglobin (HbA1c) between 8% and 10% will be randomized (1:1) to receive either an Ayurvedic Formulation, Varadi Kwath Ghana Vati, or a matched placebo, administered twice daily after meals as an adjunct to standard OHAs therapy for 180 days. The primary outcome is the mean change in HbA1c from baseline to 90 and 180 days. Secondary outcomes include the proportion of participants achieving optimal glycemic control, i.e., HbA1c ≤7%; changes in fasting C-peptide, fasting insulin, lipid profile, liver function tests, and renal function tests at baseline, 90, and 180 days. Treatment effects will be estimated as between-group differences in mean changes ± standard deviation (SD), reported with 95% confidence intervals, with statistical significance set at p < .05. DISCUSSION: Following the lead from the classical anti-diabetic action of Varadi Kwath ingredients, i.e., Haritaki (Terminalia chebula Retz), Bibhitaki [Terminalia bellirica (Gaertn.) Roxb.], Amalaki (Phyllanthus emblica L.), Daruharidra (Berberis aristata DC.), Musta (Cyperus rotundus L.), and Devdaru (Cedrus deodara Roxb. Ex D.Don). The drug will be evaluated through HbA1c and the indigenous production of C-peptide and insulin through the study.
trial registrationCTRI/2026/01/100208, Registered on: 02/01/2026, Registered Prospectively. © 2026 Wiley Periodicals LLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.